What does theabbreviation'SHR' stand for? _____________Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.Whichhypertensiveanimal modeldid we use?___________The fluorescentproductproduced in theAmplexRedassay is called______.What is theendogenousprotein we studiedthat antagonizesactivin?_____________Follistatinretains itsantioxidanteffect evenwhen denatured.True/False"In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________Hypertension isdefined bysustained bloodpressure above____ mmHg.What assay didwe use toquantifyhydrogenperoxide?_____________Our study showsthat blockingactivin signalingreduces ______production.Follistatin isknown toneutralizesignaling by______.Follistatinmust maintainits proper______ to befunctional.Our assaydirectlymeasureshydrogen______ levels.In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.FST lowersROS levels, asindicated by adecrease in______ levels.Neutralizingantibodiestargetedactivin A and______.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.Enhanced NObioavailabilityindicatesimproved______.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________FST wasadministeredevery______ day.Whichnormotensivestrain served asour control?_____________FST’santioxidanteffect is lostif it is______.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.What does theabbreviation'SHR' stand for? _____________Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.Whichhypertensiveanimal modeldid we use?___________The fluorescentproductproduced in theAmplexRedassay is called______.What is theendogenousprotein we studiedthat antagonizesactivin?_____________Follistatinretains itsantioxidanteffect evenwhen denatured.True/False"In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________Hypertension isdefined bysustained bloodpressure above____ mmHg.What assay didwe use toquantifyhydrogenperoxide?_____________Our study showsthat blockingactivin signalingreduces ______production.Follistatin isknown toneutralizesignaling by______.Follistatinmust maintainits proper______ to befunctional.Our assaydirectlymeasureshydrogen______ levels.In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.FST lowersROS levels, asindicated by adecrease in______ levels.Neutralizingantibodiestargetedactivin A and______.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.Enhanced NObioavailabilityindicatesimproved______.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________FST wasadministeredevery______ day.Whichnormotensivestrain served asour control?_____________FST’santioxidanteffect is lostif it is______.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.

Follistatin to the Rescue: Bingo for Lowering Pressure and Defeating ROS - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. What does the abbreviation 'SHR' stand for? _____________
  2. Follistatin treatment reduced blood pressure by approximately ______ mmHg.
  3. Which hypertensive animal model did we use? ___________
  4. The fluorescent product produced in the AmplexRed assay is called ______.
  5. What is the endogenous protein we studied that antagonizes activin? _____________
  6. Follistatin retains its antioxidant effect even when denatured. True/False
  7. "In our experiments, the reduction in oxidative stress was measured as a decrease in the fold change of ______.
  8. Which type of assay is used to evaluate NO levels in our study: fluorometric or colorimetric? _____________
  9. Hypertension is defined by sustained blood pressure above ____ mmHg.
  10. What assay did we use to quantify hydrogen peroxide? _____________
  11. Our study shows that blocking activin signaling reduces ______ production.
  12. Follistatin is known to neutralize signaling by ______.
  13. Follistatin must maintain its proper ______ to be functional.
  14. Our assay directly measures hydrogen ______ levels.
  15. In our study, follistatin was administered to SHRs over a period of ______ weeks.
  16. FST lowers ROS levels, as indicated by a decrease in ______ levels.
  17. Neutralizing antibodies targeted activin A and ______.
  18. Follistatin increases the expression of ______, which is critical for nitric oxide production.
  19. Enhanced NO bioavailability indicates improved ______.
  20. Which protein marker indicates a brown adipose phenotype in PVAT? _____________
  21. FST was administered every ______ day.
  22. Which normotensive strain served as our control? _____________
  23. FST’s antioxidant effect is lost if it is ______.
  24. Follistatin treatment induces ______ of PVAT, a phenotype associated with improved vascular function.